ACE Inhibitor Selection and Management for IgA Nephropathy

Introduction to ACE Inhibitor Therapy

• The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines emphasize maximizing the dose of whichever ACE inhibitor or ARB is chosen, rather than selecting a particular agent, for patients with IgA nephropathy 1
• Any ACE inhibitor is appropriate to start for IgA nephropathy, as no specific agent has proven superior—the critical factor is uptitrating to the maximally tolerated dose rather than the choice of specific drug 1, 2

Evidence-Based Rationale

• ACE inhibitors as a class provide renoprotection in IgA nephropathy, but no individual agent has been shown to be more effective than another 1, 2
• The American College of Physicians and other guideline societies recommend initiating ACE inhibitor therapy when proteinuria exceeds 1 g/day after optimizing blood pressure and implementing dietary sodium restriction to <2.0 g/day 1, 2

Treatment Algorithm

• Start any ACE inhibitor when proteinuria exceeds 1 g/day after optimizing blood pressure and implementing dietary sodium restriction to <2.0 g/day, with a goal of maximal dose tolerance, not just blood pressure control 1, 2
• Target systolic blood pressure 130/80 mmHg if proteinuria <1 g/day, or 125/75 mmHg if proteinuria ≥1 g/day 2
• Accept up to 30% increase in serum creatinine after initiation—this is hemodynamic and expected, not a reason to discontinue 2

Critical Pitfalls to Avoid

• Do not combine ACE inhibitor with ARB in IgA nephropathy, as current guidelines do not recommend this approach due to increased adverse effects without proven benefit on hard outcomes 5, 6, 7
• Do not discontinue ACE inhibitor prematurely due to modest creatinine elevation, as up to 30% increase is acceptable and reflects hemodynamic changes rather than kidney injury 2

Monitoring Requirements

• Serum potassium and creatinine should be checked within 1-2 weeks of initiation and after each dose increase 6, 7
• Blood pressure should be monitored to ensure targets are met without excessive hypotension 2
• Proteinuria should be reassessed at 3-6 months to determine need for immunosuppression escalation 1, 2

Special Populations

• Elderly patients require closer monitoring due to higher risk of hyperkalemia and hypotension, though no dose adjustment is specifically required based solely on age 6
• Pediatric patients should receive ACE inhibitor therapy when proteinuria exceeds 0.5-1 g/day per 1.73 m², with lisinopril having the most pediatric-specific evidence 8